Prospective Open-labelled Randomized Controlled trial for efficacy of cholesterol lowering intervention in CKD patient with dyslipidemia

Prospective Open-labelled Randomized Controlled trial for efficacy of cholesterol lowering intervention in CKD patient with dyslipidemia - RCT for efficacy of cholesterol lowering intervention in CKD with dyslipidemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001773

Enrollment

Registered

2009-03-16

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease patient with dyslipidemia

Interventions

Administration of pitavastatin 1mg. Increase up to 2mg, if LDL lowering effect of pitavastatin is insufficient Administration of ezetimibe 10mg. Pravastatin 10mg is add to ezetimibe 10mg, if LDL lower

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: eGFR>15ml/min urinary protein>0.5g/gcre LDL>140mg/dl

Exclusion criteria

Exclusion criteria: End stage renal disease Severe hapatic damege Hyper creatine pholphokinase Inadequate case judged by doctor

Design outcomes

Primary

Measure	Time frame
Urinary protein lowering effect Improvemant of GFR	—

Secondary

Measure	Time frame
Improvement of inflammation Improvement of oxdative stress Improvement of endothelial function	—

Countries

Japan

Contacts

Public ContactHomara Shimohata, Kouichi Hirayama

Tokyo Medical University Ibaraki Medical Center Department of Nephrology

h-shimo@tokyo-med.ac.jp029-887-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026